Assetmark Inc. Grows Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Assetmark Inc. lifted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 7.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,670 shares of the biopharmaceutical company’s stock after buying an additional 1,435 shares during the quarter. Assetmark Inc.’s holdings in Xenon Pharmaceuticals were worth $774,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets grew its position in Xenon Pharmaceuticals by 89.5% during the 1st quarter. BNP Paribas Financial Markets now owns 8,321 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 3,931 shares during the last quarter. SG Americas Securities LLC grew its position in Xenon Pharmaceuticals by 9.5% during the 1st quarter. SG Americas Securities LLC now owns 20,366 shares of the biopharmaceutical company’s stock valued at $877,000 after purchasing an additional 1,760 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in Xenon Pharmaceuticals by 21.4% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 5,374 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 946 shares during the last quarter. Russell Investments Group Ltd. grew its position in Xenon Pharmaceuticals by 2.2% during the 1st quarter. Russell Investments Group Ltd. now owns 178,099 shares of the biopharmaceutical company’s stock valued at $7,667,000 after purchasing an additional 3,813 shares during the last quarter. Finally, ProShare Advisors LLC grew its position in Xenon Pharmaceuticals by 12.0% during the 1st quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 565 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on XENE. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Raymond James reissued an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Wedbush dropped their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.45.

Xenon Pharmaceuticals Stock Down 4.6 %

Shares of NASDAQ:XENE opened at $39.83 on Friday. The firm’s 50 day moving average price is $41.18 and its 200-day moving average price is $40.36. Xenon Pharmaceuticals Inc. has a twelve month low of $28.10 and a twelve month high of $50.99. The stock has a market capitalization of $3.04 billion, a PE ratio of -14.21 and a beta of 1.25.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the firm posted ($0.73) EPS. Analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.